Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Touguinho – page 43

697 clinical trials in Touguinho, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Touguinho at a glance
697
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

697 trials in Touguinho

Open in trial search

Study on the Effectiveness and Safety of Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Phenylketonuria

Not recruiting

Study on the Long-Term Safety of PTC923 (Sepiapterin) for Patients with Phenylketonuria

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Sepiapterin
  • Sponsor:PTC Therapeutics Inc.

Study on Preventing Infections After Abdominal Surgery Using D-PLEX with Doxycycline Hyclate for Patients Undergoing Abdominal Surgery

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Doxycycline Hyclate
  • Sponsor:Polypid Ltd.

Study of Amivantamab, Lazertinib, and Drug Combination for Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer After Osimertinib Failure

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Study on the Safety and Effectiveness of Ocrelizumab vs. Fingolimod for Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Dimenhydrinate
  • Sponsor:F. Hoffmann-La Roche AG

Factor VIII deficiency+1

Not recruiting

Study on How Concizumab Works for Patients with Hemophilia A or B Without Inhibitors

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Concizumab
  • Sponsor:Novo Nordisk A/S

Study on the Safety and Effectiveness of Cibotercept (KER-012) with Other Drugs for Adults with Pulmonary Arterial Hypertension

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Cibotercept
  • Sponsor:Keros Therapeutics Inc.

Multiple sclerosis+1

Not recruiting

Study on the Effects of a Higher Dose of Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years
  • Substances:Methylprednisolone
  • Sponsor:F. Hoffmann-La Roche AG

Multiple sclerosis+2

Not recruiting

Study on the Effects of a Higher Dose of Ocrelizumab for Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years
  • Substances:Methylprednisolone
  • Sponsor:F. Hoffmann-La Roche AG

Study of Belumosudil and Prednisone for Patients Aged 12 and Older with Newly Diagnosed Chronic Graft Versus Host Disease

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on Durvalumab with Oleclumab or Monalizumab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Follicular lymphoma

Not recruiting

Study of Ibrutinib and Rituximab for Patients with Follicular Lymphoma

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Touguinho

What the registry says about research in the country

01 Mental Health Research

Clinical investigations focusing on Major Depressive Disorder (MDD) with concurrent insomnia symptoms, exploring innovative therapeutic approaches through combination treatments.

  • Depression Management
  • Sleep Disorders
  • Combination Therapy

The research evaluates the effectiveness of seltorexant as an adjunctive therapy alongside traditional antidepressants, specifically targeting patients who haven't responded adequately to standard SSRI/SNRI treatments.

02 Treatment Resistance Studies

Innovative research examining new therapeutic options for patients with treatment-resistant depression, focusing on dual-action approaches that address both mood and sleep disturbances.

  • Medication Augmentation
  • Symptom Management
  • Long-term Outcomes

The studies aim to evaluate both immediate therapeutic benefits and long-term effectiveness in preventing symptom relapse.

03 Sleep-Depression Interface

Groundbreaking research exploring the connection between sleep disorders and major depression, investigating integrated treatment approaches for better patient outcomes.

  • Sleep Quality
  • Mood Regulation
  • Combined Symptoms

These trials specifically target the dual presentation of depression and insomnia, addressing multiple symptoms through innovative pharmacological interventions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.